
    
      This Phase 2, single center, open-label research study is studying the combination of
      Anakinra and Axicabtagene Ciloleucel to reduce the occurrence of the side effects Cytokine
      Release Syndrome (CRS) and neurologic toxicities in people with relapsed or refractory
      Non-Hodgkin lymphoma (NHL).

      The research study procedures include screening for eligibility and study treatment including
      evaluations and follow up visits.

        -  This research study involves two drugs:

             -  Anakinra

             -  Axicabtagene Ciloleucel

        -  A total of 20 participants will be enrolled to this trial

        -  The U.S. Food and Drug Administration (FDA) has not approved anakinra for use in
           treatment of Non-Hodgkin lymphoma (NHL).
    
  